Login or Register for free!


Infrosoft 

Icon Home > News > News > Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer
Hi Guest
Username
Password
Icon News
Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer
Date 13/09/17/10/19  Author Newswise  Hits 14  Language Global
Newswise imageRamucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid (1) to be published in The Lancet (2).
There are no comments.

Browse Corporate Join In Elsewhere  
Home About Us Sign Up   Twitter
Search   

Health Topics Advertise with Us Blogs   facebook
Healthy Living Careers Forum  You Tube  
Health Centres Contact Us   Site Map RSS Feeds Designed & Maintained by : Student Superstars
Health Tools   Newsletter  Digg Hosted & Technical Support by : Infrosoft Technologies Pvt Ltd
Services     Delicious  Updated on: 05 May, 2017
         
         
Disclaimer : The content of the site are for informational purposes only.  Always seek the advice of a qualified physician for any doubt.

Infrosoft Copyright   |   Privacy Policy   |   Sponsor Policy    |   Editorial Policy   |    Terms of Use       ©   All Rights Reserved 2010 - 2017
         


MemHT Portal is a free software released under the GNU/GPL License by Miltenovik Manojlo